Does TOPOTECAN Cause Second primary malignancy? 23 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 23 reports of Second primary malignancy have been filed in association with TOPOTECAN (HYCAMTIN). This represents 0.7% of all adverse event reports for TOPOTECAN.
23
Reports of Second primary malignancy with TOPOTECAN
0.7%
of all TOPOTECAN reports
6
Deaths
8
Hospitalizations
How Dangerous Is Second primary malignancy From TOPOTECAN?
Of the 23 reports, 6 (26.1%) resulted in death, 8 (34.8%) required hospitalization, and 4 (17.4%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TOPOTECAN. However, 23 reports have been filed with the FAERS database.
What Other Side Effects Does TOPOTECAN Cause?
Febrile neutropenia (425)
Off label use (390)
Death (332)
Product use in unapproved indication (323)
Neutropenia (255)
Pyrexia (252)
Anaemia (242)
Malignant neoplasm progression (238)
Drug ineffective (216)
Disease progression (207)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which TOPOTECAN Alternatives Have Lower Second primary malignancy Risk?
TOPOTECAN vs TOPOTECAN\TOPOTECAN
TOPOTECAN vs TOPROL
TOPOTECAN vs TOREMIFENE
TOPOTECAN vs TORIPALIMAB
TOPOTECAN vs TORSEMIDE